Table 3 Comparisons of the predicted FCO (%) between tumor and nontumor normal samples from GEO replication data sets
From: Absence of an embryonic stem cell DNA methylation signature in human cancer
Cancer | Tumor n | Nontumor normal n | Wilcoxon rank sum test p-values | Mean age (sd) | Male n | Female n | Data source |
|---|---|---|---|---|---|---|---|
Adrenal Cortical Cancer | 18 | 6 | 0.01657 | NA | NA | NA | GSE77871 |
Bladder Cancer | 25 | 5 | 0.00162 | NA | NA | NA | GSE52955 |
Breast Cancer | 132 | 131 | 5.86E-39 | 47.31 (14.74) | 0 | 252 | GSE53051, GSE72245, GSE101961 |
Cholangiocarcinoma | 32 | 4 | 0.00108 | NA | NA | NA | GSE49656 |
Chronic Myeloid Leukemia | 12 | 11 | 0.0027 | NA | NA | NA | GSE106600 |
Colon Cancer | 35 | 18 | 3.00E-09 | 67.47 (11.26) | 5 | 2 | GSE53051 |
Esophageal Squamous Cell Carcinoma | 4 | 8 | 0.00737 | NA | 8 | 4 | GSE52826 |
Hepatocellular Carcinoma | 66 | 66 | 1.30E-13 | NA | 100 | 32 | GSE54503 |
Lung Cancer | 141 | 31 | 2.30E-12 | 63.50 (8.50) | 8 | 2 | GSE53051, GSE56044 |
Nasopharyngeal Carcinoma | 24 | 24 | 2.30E-04 | 42.96 (10.28) | 30 | 18 | GSE52068 |
Pancreatic Cancer | 29 | 12 | 7.71E-03 | 63.20 (16.24) | 7 | 3 | GSE53051 |
Prostate Cancer | 129 | 84 | 0.159 | 60.21 (7.77) | 213 | 0 | GSE52955, GSE76938, GSE112047 |
Renal Cancer | 17 | 6 | 8.80E-04 | NA | NA | NA | GSE52955 |
Rectal Cancer | 6 | 6 | 2.50E-02 | 65.50 (8.80) | 4 | 8 | GSE75546 |
Thyroid Cancer | 70 | 12 | 8.30E-07 | 48.35 (14.90) | 21 | 61 | GSE53051 |
Total | 740 | 424 | Â | Â | Â | Â | Â |